SKIN Q3 Deep Dive: Margin Expansion and Strategic Refocus Amid Device Market Headwinds

Skincare company BeautyHealth (NASDAQ:SKIN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 10.3% year on year to $70.66 million. The company’s full-year revenue guidance of $296.5 million at the midpoint came in 0.8% above analysts’ estimates. Its GAAP loss of $0.09 per share was in line with analysts’ consensus estimates.

Is now the time to buy SKIN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

BeautyHealth’s third quarter saw the company outperform Wall Street’s revenue expectations, despite a double-digit year-over-year sales decline. The market’s positive reaction reflected management’s focus on stabilizing the core Hydrafacial business and shifting to higher-margin recurring consumables. CEO Pedro Malha credited “strong operational execution and disciplined cost management” for improved operating margins, as well as the successful transition to a distributor model in China, which helped streamline inventory and reduce exposure to tariffs. Management highlighted booster product innovation and a growing installed device base as bright spots, even as device sales remained pressured by cautious consumer spending and financing challenges.

Looking ahead, BeautyHealth’s raised full-year guidance is underpinned by efforts to drive consumable utilization, ongoing product innovation, and a sharpened focus on operational discipline. Management plans to prioritize expanding the Hydrafacial device footprint and capturing recurring revenues from consumables, particularly through clinically backed booster products. CEO Pedro Malha noted, “Our intent is to continue to launch superior, and most importantly, clinically backed products that meet our provider needs.” However, management remains watchful of macroeconomic uncertainty, particularly regarding consumer confidence and the lending environment for capital equipment purchases, which could impact the pace of device placements.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to lower device sales, a more favorable sales mix from recurring consumables, and disciplined expense controls. Strategic changes in China and a pause on non-core initiatives also shaped results.

• Device sales under pressure: BeautyHealth experienced a continued decline in device placements, largely due to macroeconomic challenges including tighter lending conditions and reduced discretionary spending, particularly in the Americas and EMEA regions.
• Consumables driving profitability: The shift in business mix towards consumables—products used repeatedly with Hydrafacial devices—boosted overall margins. New booster products, like Hydralock HA and HydraFillic with Pep9, contributed to double-digit growth in the booster category, and the consumables segment now represents 71% of total sales.
• Strategic China transition: The company completed its shift from direct sales to a distributor model in China, reducing exposure to tariffs and stabilizing inventory. While this change initially weighed on revenue, management expects it to drive more predictable, recurring revenue streams over time.
• Cost discipline and margin improvement: Operating expenses declined significantly year-over-year, with lower headcount and targeted spending in sales, marketing, and general administration. This, alongside improved demand planning and inventory management, led to a notable improvement in operating margin and adjusted EBITDA.
• Pause on skincare initiative: Management decided to halt the development of a proprietary skincare line, opting instead to focus capital and resources on core device and consumable offerings. CEO Pedro Malha emphasized that this move “preserves capital, which indeed will absolutely help us in our near-term profitability profile.”

Drivers of Future Performance

BeautyHealth’s outlook is shaped by expectations for gradual device market stabilization, increased consumable utilization, and ongoing new product launches—balanced against ongoing macroeconomic headwinds.

• Device market stabilization efforts: Management believes that stabilizing device sales will depend on improved access to financing for providers and continued refinement of pricing strategies. The recently introduced “good, better, best” device portfolio aims to offer more flexibility to customers and help navigate challenging economic conditions.
• Consumables and product innovation focus: Future growth is expected to be driven by the company’s recurring consumables business, with a particular emphasis on launching clinically backed boosters and strengthening provider education and training. Management sees innovation in boosters as key to increasing utilization rates across the installed device base.
• Macroeconomic and competitive risks: The company remains cautious around persistent inflation, uneven consumer confidence, and a crowded competitive landscape, especially in EMEA. Management is also monitoring churn rates among smaller providers, which remain higher than historical averages, and is implementing targeted training and support to mitigate this risk.

Catalysts in Upcoming Quarters

Moving forward, our analysts will closely watch (1) the pace of recovery in device placements across key geographies, (2) sustained growth in consumables utilization—especially booster products, and (3) further evidence of margin expansion driven by disciplined cost management and operational improvements. Additionally, developments in provider financing options and the resolution of elevated churn rates among smaller accounts will be important signposts for the business.

BeautyHealth currently trades at $1.36, up from $1.29 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.